P2B-001 Market Size, Forecast, and Emerging Insight - 2032

This “P2B-001 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about P2B-001 for Parkinson's disease in the seven major markets. A detailed picture of the P2B-001 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the P2B-001 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the P2B-001 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary

P2B-001 being developed by Pharma Two B, is a novel, once-daily combination of extended-release pramipexole, a low-dose dopamine agonist, and rasagiline, a low-dose Monoamine Oxidase-B (MAO-B) inhibitor, developed specifically for the treatment of Parkinson's disease.

The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each drug. Lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs in an improved formulation that is hoped to be more effective in controlling Parkinson's disease symptoms and with fewer side effects than each of the drugs taken alone or the currently available commercial drugs taken together.

Pharma Two B has completed Phase IIb and Phase III studies investigating P2B001's efficacy and safety as a once-daily, no-titration treatment for early-stage Parkinson's disease. An NDA submission to the FDA is being prepared. In a previously completed clinical trial, a significant improvement in Parkinson's disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with a placebo.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the P2B-001 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on P2B-001 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the P2B-001 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around P2B-001.
• The report contains forecasted sales of P2B-001 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for P2B-001 in Parkinson's disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

P2B-001 Analytical Perspective

In-depth P2B-001 Market Assessment

This report provides a detailed market assessment of P2B-001 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

P2B-001 Clinical Assessment

The report provides the clinical trials information of P2B-001 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence P2B-001 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to P2B-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of P2B-001 in Parkinson's disease.
• This in-depth analysis of the forecasted sales data of P2B-001 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the P2B-001 in Parkinson's disease.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of P2B-001?
• What is the clinical trial status of the study related to P2B-001 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the P2B-001 development?
• What are the key designations that have been granted to P2B-001 for Parkinson's disease?
• What is the forecasted market scenario of P2B-001 for Parkinson's disease?
• What are the forecasted sales of P2B-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to P2B-001 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

This product will be delivered within 2 business days.